Yazar "Tanriverdi, Lokman H." seçeneğine göre listele
Listeleniyor 1 - 13 / 13
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acute and Subacute Effects of Low Versus High Doses of Standardized Panax ginseng Extract on the Heart: An Experimental Study(Humana Press Inc, 2019) Parlakpinar, Hakan; Ozhan, Onural; Ermis, Necip; Vardi, Nigar; Cigremis, Yilmaz; Tanriverdi, Lokman H.; Colak, CemilPanax ginseng is commonly used in Chinese medicine and Western herbal preparations. However, it has also been recently noted to be associated with some cardiac pathologies-including cardiogenic shock due to acute anterior myocardial infarction, trans-ischemic attack, and stent thrombosis. This study was aimed to elucidate acute and subacute effects of the low and high doses of standardized Panax ginseng extract (sPGe) on cardiac functions. Rats were randomly assigned to control group, acute low-dose group (ALD), subacute low-dose group (SALD), acute high-dose group (AHD), and subacute high-dose group (SAHD). The cardiac effects of sPGe were evaluated using hemodynamic, biochemical, echocardiographic, genetic, and immunohistopathologic parameters. Mean blood pressures were significantly lower in all sPGe-treated groups compared with the control group. Troponin I and myoglobin levels were increased in the SALD, AHD, and SAHD groups. Mitral E-wave velocity was reduced after sPGe administration in all the groups. Acidophilic cytoplasm and pyknotic nucleus in myocardial fibers were observed in AHD and SAHD groups. Cu/Zn-SOD1 gene expressions were significantly higher in the sPGe-treated groups whereas caveolin 1 and VEGF-A gene expressions were not changed. According to our results, sPGe may have a potential effect to cause cardiac damage including diastolic dysfunction, heart failure with preserved ejection fraction, and reduction of blood pressure depending on the dose and duration of usage. Healthcare professionals must be aware of adverse reactions stemming from the supplementation use, particularly with cardiac symptoms.Öğe Aldosterone Synthase Inhibitors Effectively Lower Blood Pressure but Increase Hyperkalemia Risk: A Meta-Analysis of Randomized Trials(Lippincott Williams & Wilkins, 2025) Tanriverdi, Lokman H.; Dogan, Muhammed Melih; Hernandez, Adrian V.; Balkar, Mehmet Ertugrul; Tay, Emir Omer; Ospina, Carlos Alberto Calderon; Banach, Maciej[No abstract available]Öğe Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis(Elsevier, 2025) Sarici, Ahmet; Tanriverdi, Lokman H.; Hernandez, Adrian, V; Altuntas, Fevzi; Saglio, Giuseppe[No abstract available]Öğe Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials(Elsevier Science Inc, 2025) Tanriverdi, Lokman H.; Barrett, Annie; Kalyanasundaram, Asanish; Zafar, Mohammad A.; Ziganshin, Bulat A.; Elefteriades, John A.Objective: Studies investigating the efficacy of beta-blocker agents for patients with thoracic aortic aneurysm (TAA) have produced heterogeneous and conflicting results. We assess the effects of beta-blockers on clinical outcomes in patients with TAA. Methods: A systematic literature search was performed through Ovid MEDLINE, EMBASE, Web of Science, Pubmed and Cochrane CENTRAL, all from inception to April 30, 2024. Randomized controlled trials (RCTs) exploring the effect of beta-blocker agents in patients with TAA were considered for inclusion, with no population restriction. Inverse variance-weighted random-effects model was used. The overall risk of bias assessment was conducted by Cochrane Risk of Bias 2 tool. The primary outcome was aortic events during follow-up. Results: We included a total of 161 patients with TAA (mean age, 27.6 years; 80 [49.7 %] male, mean follow-up 6.7 years) in 4 RCTs. The pooled risk ratio in the beta-blocker arm for aortic events was 0.74 [95 % CI (0.20; 2.71), I-2: 0 %, p = 0.64, low certainty of evidence (CoE)] when compared to placebo or no treatment in patients with TAA. The pooled risk ratios for aortic dissection or death (all-cause mortality) or in the beta-blocker arm were 0.45 (95 % CI (0.10; 1.98), I-2: 0 %, p = 0.29, low CoE) and 0.58 (95 % CI (0.15; 2.24), I-2: 0 %, p = 0.43, low CoE), respectively. The risks of aortic dissection, rupture, or death were comparable, regardless of agent, disease, and age. Conclusion: We found no evidence of benefit from beta-blocker treatment for patients with TAA. More robust RCTs are needed to establish evidence-based recommendations.Öğe Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials(Mdpi, 2026) Tanriverdi, Lokman H.; Sarici, Ahmet; Aksan, Feyzullah; Hernandez, Adrian V.Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments. Methods: We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety of FDM vs. IS in patients with IDA. The primary efficacy outcome was the change in hemoglobin (Hb) levels at week 4, and the safety outcome was serious or severe hypersensitivity reactions, as defined by a standardized set of Medical Dictionary for Regulatory Activities (MedDRA) terms. Inverse-variance random effects models were used for meta-analyses. Results: Five RCTs were included: two in general IDA (n = 1994), two in non-dialysis chronic kidney disease (n = 1542), and one in hemodialysis patients (n = 344). The evidence was very uncertain about the effect of FDM vs. IS for Hb change at week 4 (mean difference [MD] 0.09 g/dL, 95% CI -0.33 to 0.52; I2 = 84%, very low CoE), serious or severe hypersensitivity reactions (MedDRA A + B + C + D, relative risk [RR] 0.83, 95% CI 0.25 to 2.68; I2 = 0%, very low CoE), Hb change at week 8 (MD 0.04 g/dL, 95% CI -0.08 to 0.15; I2 = 0%, very low CoE), Hb increase of >= 2 g/dL at week 4 (RR 1.16, 95% CI 0.97 to 1.38; I2 = 70%, very low CoE), and anaphylactic reactions (MedDRA A, RR 0.38, 95% CI 0.08 to 1.72; I2 = 0%, very low CoE). Conclusions: We found that FDM vs. IS had little to no effect on outcomes for the treatment of IDA.Öğe Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study(Springer, 2025) Aksan, Feyzullah; Abboud, Alan; Tanriverdi, Lokman H.; Aroniadis, Olga C.; Monzur, FarahGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated anti-inflammatory effects in preclinical models of inflammatory bowel disease (IBD), yet clinical data remain limited. This study aimed to assess the association between GLP-1 RAs exposure and disease-related outcomes, treatment patterns, and healthcare utilization in patients with IBD. We conducted a retrospective, propensity score-matched cohort study using data from the TriNetX Analytics Research Network. Adults diagnosed with Crohn's disease or ulcerative colitis between 2006 and 2022 were matched 1:1 based on GLP-1 RAs exposure. Patients with confounding comorbidities were excluded. Key outcomes included 5-year mortality, IBD-related surgeries and complications, medication use, and healthcare utilization. A total of 11,016 matched IBD patients were included (GLP-1 RAs: n = 5508; no GLP-1 RAs: n = 5508). Exposure to GLP-1 RAs was associated with a significantly lower 5-year mortality rate (8.05% vs 10.03%, hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.54-0.78, p < 0.0001). Rates of IBD-related surgeries (HR 0.53, 95% CI 0.39-0.72) and complications (HR 0.81, 95% CI 0.70-0.93) were also reduced. Moreover, patients in the GLP-1 RAs group experienced fewer overall healthcare encounters (chi(2) = 136.52, p < 0.0001). Significant differences were observed in corticosteroid (p < 0.0001) and advanced biologic use (p < 0.0001), although rank biserial correlation was small (0.04 and - 0.11, respectively), and findings on medication use did not persist in subgroup analyses of ulcerative colitis and Crohn's disease patients. Our findings suggest a potential disease-modifying effect of GLP-1 RAs beyond glycemic control, especially in reducing mortality, complications, surgeries, and healthcare use. However, the clinical relevance of reduced medication use warrants further investigation through prospective trials.Öğe The impact of smartphone applications on bowel preparation, compliance with appointments, cost-effectiveness, and patients' quality of life for the colonoscopy process: A scoping review(Wolters Kluwer Medknow Publications, 2023) Aksan, Feyzullah; Tanriverdi, Lokman H.; Figueredo, Carlos Jose; Barrera, Layla C.; Hasham, Alia; Jariwala, Sunit P.The aim of this scoping review is to evaluate the impact of smartphone application (SPA) technology in patients undergoing elective colonoscopy to measure compliance with appointments, cost-effectiveness, bowel preparation, and quality of life. The scoping review was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. Ovid Medline, Web of Science, Science Direct, Scopus, Cochrane Library, and PubMed were screened up to Oct 14, 2020, and bibliographies of the retrieved articles were included. Based on pre-specified inclusion and exclusion criteria, 8 primary studies were included in the final analysis from a total of 3,979 non-duplicate articles. Seven out of eight studies measured the bowel preparation quality. In six of these studies, patients in the smartphone group had a successful bowel preparation when compared with the control arm; on the other hand, one study did not find any differences between groups. Adherence to colonoscopy screening was assessed by one study. Patients in the digital intervention arm were significantly more likely to complete a screening test. Patient satisfaction during the periprocedural period of colonoscopy was assessed by five studies which reported significantly higher patient satisfaction in the intervention arm compared to the control arm. None of the studies measured cost-effectiveness. We came to the conclusion that a well-designed, user-friendly SPA can help and guide patients undergoing colonoscopy through the process of following up on their appointments, adhering to bowel preparation, and better understanding their disease condition. Future trials investigating SPAs should include cost-effectiveness and adherence to appointments as an endpoint.Öğe Inhibition of NADPH oxidase by apocynin promotes myocardial antioxidant response and prevents isoproterenol-induced myocardial oxidative stress in rats(Taylor & Francis Ltd, 2017) Tanriverdi, Lokman H.; Parlakpinar, Hakan; Ozhan, Onural; Ermis, Necip; Polat, Alaadin; Vardi, Nigar; Tanbek, KevserPreventive and/or therapeutic interventions for ischemic heart disease have gained considerable attention worldwide. We investigated the mechanism(s) underlying cardioprotection of apocynin (APO) and whether it attenuates isoproterenol (ISO)-induced myocardial damage in vivo. Thirty-two male Wistar Albino rats were randomised into four groups (n = 8 for each group): Group I (Control); Group II (ISO), ISO was given intraperitoneally (ip) (150 mg/kg/d) daily for 2 consecutive days; Group III (APO+ISO), APO was applied ip 20 mg/kg 30 min before the first ISO administration and continued for the next 2 d after the second ISO administration; Group IV (ISO+APO), after the ISO treatment on days 1 and 2, 20 mg/kg APO was given ip on days 3 and 4. Cardioprotective effects of APO were evaluated by biochemical values, histopathological observations and the antiapoptotic relative proteins. Mean blood pressure, heart rate, and electrocardiography (ECG) were also monitored. Malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), total oxidant status (TOS), total antioxidant capacity (TAC), oxidative stress index (OSI), caspase-3 and connexin 43 levels were determined. Major ECG changes were observed in the ISO-treated rats. MDA, TOS, OSI and creatine kinase levels decreased and SOD, CAT, GSH and TAC levels increased, indicating that APO reduced cardiac injury and oxidative stress compared with controls. APO also decreased the number of cardiomyocytes with pyknotic nuclei, inflammatory cell infiltration, intracytoplasmic vacuolisation and myofibrils. APO provides preventive and therapeutic effects on ISO-induced myocardial injury in rats by inhibiting reactive oxygen species production, blocking inflammation and enhancing antioxidant status.Öğe No-Touch Saphenous Vein Grafting Reduce Occlusion Risk but Increase Leg Wound Complications in Coronary Artery Bypass Grafts: A Meta-Analysis(Lippincott Williams & Wilkins, 2025) Dogan, Muhammed Melih; Tanriverdi, Lokman H.; Balkhy, Husam[No abstract available]Öğe Olpasiran Outperforms Other Subcutaneous Lipoprotein(a)-Lowering Agents in Efficacy and Safety: A Network Meta-Analysis of Randomized Controlled Trials(Lippincott Williams & Wilkins, 2025) Tanriverdi, Lokman H.; Dogan, Muhammed Melih; Su, Angela; Shan, Ryan; Banach, Maciej; Hernandez, Adrian V.[No abstract available]Öğe Protective and therapeutic effects of dexpanthenol on isoproterenol-induced cardiac damage in rats(WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2018) Kalkan, Ferhat; Parlakpinar, Hakan; Disli, Olcay M.; Tanriverdi, Lokman H.; Ozhan, Onural; Polat, Alaaddin; Cetin, Asli; Vardi, Nigar; Otlu, Yilmaz O.; Acet, AhmetThe purpose of the study was to explore the protective and therapeutic effects of dexpanthenol (DEX) on isoproterenol (ISO)-induced cardiac damage. Forty rats were distributed into four groups: group I (Control); group II (ISO); ISO (150mg/kg/day) was given to rats once a day for 2 consecutive days with an interval of 24h; group III (DEX+ISO): DEX (250mg/kg) was applied 30min before the first ISO administration and continued in the next two days after second ISO administration; group IV (ISO+DEX): After the ISO treatment at 1st and 2nd days, DEX was given at 3rd and 4th days. Rats were monitored for mean arterial blood pressure (BP), heart rate, oxygen saturation (%SO2), and electrocardiography (ECG). Heart tissue levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), reduced glutathione (GSH), total oxidant status (TOS); total antioxidant capacity (TAC), oxidative stress index (OSI), and caspase-3 were determined. BP and SO2 values indicated a significant decrease in the ISO group. Also, T wave negativity was observed in 6 of 10 rats, SOD, CAT, and GPX levels were significantly lower in ISO group than control group. ISO administration increased TOS and OSI levels, whereas DEX treatment significantly reduced these parameters. Also, ISO-induced morphological alterations such as disorganization of cardiomyocytes, loss of myofibrils and cytoplasmic vacuolization whereas these histological damages were significantly decreased in ISO+DEX and DEX+ISO groups when compared to the ISO group. This study implies the cardioprotective effects of DEX on ISO-induced cardiotoxicity.Öğe Protective and therapeutic effects of dexpanthenol on isoproterenol-induced cardiac damage in rats(Wiley, 2018) Kalkan, Ferhat; Parlakpinar, Hakan; Disli, Olcay M.; Tanriverdi, Lokman H.; Ozhan, Onural; Polat, Alaaddin; Cetin, AsliThe purpose of the study was to explore the protective and therapeutic effects of dexpanthenol (DEX) on isoproterenol (ISO)-induced cardiac damage. Forty rats were distributed into four groups: group I (Control); group II (ISO); ISO (150mg/kg/day) was given to rats once a day for 2 consecutive days with an interval of 24h; group III (DEX+ISO): DEX (250mg/kg) was applied 30min before the first ISO administration and continued in the next two days after second ISO administration; group IV (ISO+DEX): After the ISO treatment at 1st and 2nd days, DEX was given at 3rd and 4th days. Rats were monitored for mean arterial blood pressure (BP), heart rate, oxygen saturation (%SO2), and electrocardiography (ECG). Heart tissue levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), reduced glutathione (GSH), total oxidant status (TOS); total antioxidant capacity (TAC), oxidative stress index (OSI), and caspase-3 were determined. BP and SO2 values indicated a significant decrease in the ISO group. Also, T wave negativity was observed in 6 of 10 rats, SOD, CAT, and GPX levels were significantly lower in ISO group than control group. ISO administration increased TOS and OSI levels, whereas DEX treatment significantly reduced these parameters. Also, ISO-induced morphological alterations such as disorganization of cardiomyocytes, loss of myofibrils and cytoplasmic vacuolization whereas these histological damages were significantly decreased in ISO+DEX and DEX+ISO groups when compared to the ISO group. This study implies the cardioprotective effects of DEX on ISO-induced cardiotoxicity.Öğe S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis(Lippincott Williams and Wilkins, 2025) Tanriverdi, Lokman H.; Aksan, Feyzullah; Aroniadis, Olga; Monzur, FarahObjectives: – This systematic review and meta-analysis aimed to evaluate the efficacy and safety of sphingosine-1-phosphate (S1P) receptor modulators for achieving clinical remission and key outcomes in inflammatory bowel disease (IBD) patients and to examine the influence of baseline characteristics. Methods: – MEDLINE (Ovid), PubMed, Web of Science, and Cochrane CENTRAL were searched until January 1, 2024. Randomized controlled trials (RCTs) evaluating S1P receptor modulators in adult IBD patients were included. Meta-analyses used inverse variance random-effects models, with stratified analyses by disease type, prior anti-TNF use, corticosteroid use, disease location, and baseline Mayo score. Results: – Six RCTs involving 1744 patients (male: 58.8%; age: 41.1±13.5 y) were analyzed. S1P modulators significantly improved clinical remission versus placebo in induction (RR: 2.22; 95% CI: 1.30-3.80) and maintenance phases (RR: 2.79; 95% CI: 1.72-4.54). For UC patients, induction remission was notably higher with S1P modulators (RR: 2.69; 95% CI: 1.98-3.65). Stratified analyses indicated consistent efficacy across disease location (P=0.15), corticosteroid use (P=0.20), and Mayo scores (P=0.53). Prior anti-TNF-naive patients experienced greater benefits (P=0.04). Maintenance-phase remission rates favored etrasimod (RR: 4.26; 95% CI: 2.36-7.69) over ozanimod (RR: 2.09; 95% CI: 1.54-2.84; P=0.035). Secondary outcomes, including clinical response, endoscopic and histologic remission, mucosal healing, and corticosteroid-free remission, were also significantly improved. Overall, adverse events were more frequent with S1P modulators (RR: 1.18; 95% CI: 1.07-1.30); serious adverse events, infections, mortality, and cardiac events were comparable. Conclusions: – S1P modulators improved remission rates and secondary outcomes in UC with a generally favorable safety profile. More data on CD are needed. © 2025
